Bragar Eagel & Squire, P.C. Reminds GRAIL, Inc. Investors They Have Until August 4th to Contact the Firm Seeking Lead Plaintiff Rol

A class action lawsuit has been filed against GRAIL, Inc. alleging that the company provided materially false and misleading statements regarding its NHS Galleri trial results. The complaint claims GRAIL concealed that the trial period was insufficient to demonstrate a reduction in Stage III-IV cancers. On February 19, 2026, GRAIL announced that the primary endpoint was not achieved, causing the stock price to fall significantly. Investors who purchased shares between May 13, 2025, and February 19, 2026, have until August 4, 2026, to apply as lead plaintiff.